Key facts
- Cytogel Pharma’s last known valuation is $47.0M (Oct 2024).
- It has raised $32.8M across 4 recorded rounds; the latest was Seed Round ($1.8M) in Jun 2023.
- Notable investors include New Ground Ventures, Westway Capital, Centripetal Capital Partners, Cytogel Venture, John Fernandes.
- Cytogel Pharma has filed 14 Form Ds with the SEC since 2010, most recently Oct 2024 ($1.8M sold to 18 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Cytogel Pharma
Funding rounds
4 roundsAbout Cytogel Pharma
Operator of a bio-pharmaceutical company intended to assist with the discovery and development of safe and innovative treatments to finally resolve moderate to severe pain. The company offers significant potential both as platform technologies, value product candidates, and drug delivery hydrogels that represent a breakthrough in the treatment of pain, enabling patients to get treatment properly, resulting in a likelihood of successful treatment.
- Sector
- Healthcare
- HQ
- Darien, CT, United States
- Founded
- 2006
- Employees
- 9
- Website
- cytogelpharma.com/
- Ownership
- Privately Held (backing)
Cytogel Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cytogel Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cytogel Pharma in its N-PORT filings yet. We sweep new filings monthly.